Advances in diagnosis and management of oligodendroglioma

References

• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int.j Cancer 83(6), 870–873 (1999).
   Google Scholar
• Greenlee RE Murray T Cancer statistics, 2001. CA Cancer 1 Clin. 51(1), 15–36 (2001).
   Google Scholar
• Coons SW Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7), 1381–1393 (1997).
   PubMed Web of Science ®Google Scholar
• •Emphasizes the fact that accurate histologic diagnosis of gliomas is fundamental to proper patient management and to the interpretation of basic and clinical investigations. The authors' data indicate that oligodendroglial tumors comprise up to 25% of gliomas, a significantly higher proportion than was previously recognized.
   Google Scholar
• Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JR Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. Neumoncol 34(1), 37–59 (1997).
   Google Scholar
• Daneyemez M, Baysefer A, Can C, Timurkaynak E. Multiple oligodendroglioma: case report. Minimum Invasive Neurosurg. 43(1), 51–52 (2000).
   Google Scholar
• Chen R, MacDonald DR, Ramsay DA. Primary diffuse leptomeningeal oligodendroglioma. I Neurosurg. 83,724–728 (1995).
   PubMed Web of Science ®Google Scholar
• Olson JD, Riedel E, DeAngelis LM. Long- term outcome of low-grade oligodendroglioma and mixed glioma.Neurology54(7), 1442–1448 (2000).
   PubMed Web of Science ®Google Scholar
• ••Discussed the optimal timing andeffectiveness of initial treatment in low-grade oligodendrogliomas and mixed gliomas. It concluded that there were no apparent differences in either immediate versus deferred treatment on disease-free or overall survival.
   Google Scholar
• Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch. Neural. 56 (4), 434–436 (1999).
   Google Scholar
• Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW Grading of oligodendrogliomas. Cancer 52,2107–2114 (1983).
   PubMed Web of Science ®Google Scholar
• Bruner JM. Oligodendrgliomas: diagnosis and prognosis. Semin. Diag. Athol 4,251–261 (1987).
   PubMed Web of Science ®Google Scholar
• Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW A clinicopathological study of 323 patients with oligodendrogliomas. Ann. Neural. 19, 15–21 (1986).
   Google Scholar
• Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J. Neural. Exp. Neural. 45,65–78 (1986).
   PubMedGoogle Scholar
• Kleihues P, Cavenee WK. Pathology and genetics. In: TUMOIN of the Nervous System. Kleihues P, Cavenee W (Eds), Inter-national Agency for Research on Cancer, Lyon, France, (1997).
   Google Scholar
• Daumas-Duport C, Tucker ML, Kolles H et al Oligodendrogliomas. Part II. A new grading system based on morphological and imaging criteria. J. Neurooncol 34,61–68 (1997).
   Google Scholar
• Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. Springer, Berlin Heidelberg New York, NY, USA, 1–105 (1993).
   Google Scholar
• Bello MJ, Leone PE, Vaquero J et al Allelic loss at lp and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int.j Cancer 64 (3), 207–210 (1995).
   Google Scholar
• Bigner SH, Matthews MR, Rasheed BK et al Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am. J. Pathol 155(2), 375–386 (1999).
   Google Scholar
• •Attempts to define molecular profiles of oligodendrogliomas by using comparative genomic hybridization and to determine whether there is a relationship between molecular genetic parameters and histological pattern in this tumor type.
   Google Scholar
• Kraus JA, Koopmann J, Kaskel P et al Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. Neuropathol Exp. Neural 54(1), 91–95 (1995).
   Google Scholar
• Maintz D, Fiedler K, Koopmann J et al Molecular genetic evidence for subtypes of oligoastrocytomas. I Neuropathol Exp. Neural 56(10), 1098–1104 (1997).
   Web of Science ®Google Scholar
• Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and lp. Am. J. Pathol 145(5), 1175–1190 (1994).
   Google Scholar
• Smith JS, Alderete B, Minn Y et al Localization of common deletion regions on lp and 19q in human gliomas and their association with histological subtype. Oncogene 18(28), 4144–4152 (1999).
   Google Scholar
• Nigro JM, Takahashi MA, Ginzinger DG et &Detection of lp and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am.J. Pathol 158 (4), 1253–1262 (2001).
   Google Scholar
• Smith JS, Perry A, Borell TJ et al Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. j Clin. Oncol 18(3), 636–645 (2000).
   Google Scholar
• ••Suggests that combined loss of lp and 19qis a predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade.
   Google Scholar
• Wu JK, Folkerth RD, Ye Z, Darras BT Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. I Neurooncol 15(1), 29–35 (1993).
   Google Scholar
• Kros JM, van Run PR, Alers JC et al Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH) .J Pathol 188(3), 282–288 (1999).
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Santarius T, Wu X et al Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 21 (3), 207–216 (1998).
   PubMed Web of Science ®Google Scholar
• Caimcross JG, Ueki K, Zlatescu MC et al Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. j Natl Cancer Inst. 90(19), 1473–1479 (1998).
   Google Scholar
• Jeuken JW, Sprenger SH, Wesseling P et al Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. I Neuropathol Exp. Neural 58(6), 606–612 (1999).
   Web of Science ®Google Scholar
• Rosso SM, van Dekken H, Krishnadath KK, Alers JC, Kros JM. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. Neuropathol Exp. Neural 56(10), 1125–1131 (1997).
   Web of Science ®Google Scholar
• Pruchon E, Chauveinc L, Sabatier L et al A cytogenetic study of 19 recurrent gliomas. Cancer Genet. Cytogenet. 76(2), 85–92 (1994).
   Google Scholar
• Broholm H, Bols B, Heegaard S, Braendstrup 0. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas. Clin. Neuropathol 18(4), 176–180 (1999).
   Google Scholar
• Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP Epidermal growth factor receptor expression in oligodendroglial tumors. Am. Pathol 149(1), 29–35 (1996).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt PC. Evaluation of cell proliferation, epidermal growth factor receptor and bc1-2 immunoexpression as prognostic factors for patients with World Health Organization Grade 2 oligodendroglioma. Cancer 88(4), 862–869 (2000).
   Google Scholar
• Wang Y, Hagel C, Hamel W, Muller S, Kluwe L, Westphal M. Trk A, B and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol Merl). 96 (4), 357–364 (1998).
   Google Scholar
• Zhou XP, Li YJ, Hoang-Xuan K et al Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. I Cancer 84 (2), 150–154 (1999).
   PubMed Web of Science ®Google Scholar
• Ino Y, Betensky RA, Zlatescu MC et al Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839–845 (2001).
   PubMed Web of Science ®Google Scholar
• Bello MJ, Vaquero J, de Campos JM et al Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of lp in oligodendroglial tumors. Int. Cancer 57(2), 172–175 (1994).
   Google Scholar
• Guan KL, Jenkins CW, Li Y et al Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild type pRb function. Genes Dev. 8(24), 2939–2952 (1994).
   Google Scholar
• He J, Hoang-Xuan K, Marie Y et al. p18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 55(6), 867–869 (2000).
   Google Scholar
• Barker FG, Chang SM, Huhn SL et al Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer80, 936–941 (1997) .
   PubMed Web of Science ®Google Scholar
• Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DE The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg. Neural 49,436–440 (1998).
   PubMedGoogle Scholar
• Dehghani F, Schachenmayr W, Laun A, Korf HW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95(5), 493–504 (1998).
   Google Scholar
• Heegaard S, Sommer HM, Broholm H, Broendstrup 0. Proliferating cell nuclear antigen and 1(1–67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10), 1809–1013 (1995).
   Google Scholar
• Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen 1(1–67 in oligodendrogliomas. Cancer 78 (5), 1107–1113 (1996).
   Google Scholar
• Coons SW Johnson PC, Pearl DK. The prognostic significance of 1(1–67 labeling indices for oligodendrogliomas. Neurosurgery41 (4), 878–884 (1997).
   Google Scholar
• Miettinen H, Kononen J, Sallinen P et al CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. j Neurooncol 41(3), 205–211 (1999).
   Google Scholar
• Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42 (2), 341–346 (1998).
   PubMed Web of Science ®Google Scholar
• Deininger MH, Weller M, Streffer J, Meyermann R. Anti-apoptotic Bc1-2 family protein expression increases with progression of oligodendroglioma. Cancer 86(9), 1832–1839 (1999).
   Google Scholar
• Dehghani F, Maronde E, Schachenmayr W, Korf HW. Neurofilament H immunoreaction in oligodendrogliomas as demonstrated by a new polydonal antibody. Acta Neuropathol 100(2), 122–130 (2000).
   PubMed Web of Science ®Google Scholar
• Korshunov A, Golanov A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. Neurooncol 48(1), 13–19 (2000).
   Google Scholar
• Fleury A, Menegoz F, Grosclaude P et al Descriptive epidemiology of cerebral gliomas in France. Cancer 79,1195–1202 (1997).
   PubMed Web of Science ®Google Scholar
• Allam A, Radwi A, El Weshi A, Hassounah M. Oligodendroglioma: an analysis of prognostic factors and treatment results. Am. Clin. Oncol 23(2), 170–175 (2000).
   Google Scholar
• Marek J, Jakubaszko-Turkiewicz J, Oficjalska-Mlynczak J, Markowska-Woyciechowska A. Retinal oligodendroglioma. Am J. Ophthalmol 128(3), 389–391 (1999).
   Web of Science ®Google Scholar
• Derlon JM, Chapon F, Noel M et al. Non- invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur: J. Nucl. Merl 27(7), 778–787 (2000).
   Google Scholar
• Holzer T The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using f-18-fluorodeoxyglucose and c-11-L-methylmethionine. Neurosurgery 42(5), 1200–1201 (1998).
   Google Scholar
• Herholz K, Holzer T, Bauer B et all1C- methionine PET for differential diagnosis of low-grade gliomas. Neurology50(5), 1316–1322 (1998).
   Google Scholar
• Bader JB, Samnick S, Moringlane JR et al Evaluation of1-3- [1231] iodo-a-methyltyrosine SPET and [18F1 fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. EurNucl. Merl 26(2), 144–151 (1999).
   Google Scholar
• Shaw EG, Scheithauer BW, 0Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo clinic experience. I Neurosury. 76,428-434 (1992).
   Google Scholar
• Whitton AC, Bloom HJG. Low-grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. J. Int. J. Racliat. Oncol Biol. Phys. 18,783-786 (1990).
   Google Scholar
• Apuzzo MU. Evolving dimensions at the frontiers of human cerebral surgery. In: Benign Cerebral Clioma. Neumsurgical Topics. Apuzzo MU J (Ed.). Am. Ass. Nemo'. Surg. 1–12 (1995).
   Google Scholar
• Ganslandt 0, Steinmeier R, Kober H. et al. Magnetic source imaging combined with image-guided frameless stereotaxy: a new method in surgery around the motor strip. Neurosurgery 41 (3), 621–628 (1997).
   Google Scholar
• Caimcross G, Macdonald D, Ludwin S et al Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Clin. Oncol 12(10), 2013–2021 (1994). Phase II clinical trial concluded that anaplastic oligodendrogliomas are chemosensitive tumors. Patients with these tumors responded predictably, durably and often completely to PCV.
   Google Scholar
• Soffietti R, Borgogne M, Bradac GB, Schiffer D. Role of chemotherapy in oligodendroglial tumors: a review of the experience at the University ofTorino. Neurooncol 30,153 (1996).
   Google Scholar
• Mason WP, Krol GS, DeAngelis LM. Low- grade oligodendroglioma responds to chemotherapy. Neurology46,203–207 (1996).
   Google Scholar
• Duffau H, Albuquerque L, Amen A, Sanson M, Poisson M, Delattre J-Y. Chemotherapy for newly diagnosed and recurrent anaplastic oligodendrogliomas and mixed gliomas: an analysis of 42 cases. Neurology 45 (Suppl. 4), A261 (1995).
   Google Scholar
• Streffer J, Schabet M, Bamberg M et al A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J. Neural 247 (4), 297–302 (2000).
   PubMed Web of Science ®Google Scholar
• Wang Y, Hagel C, Hamel W, Kluwe L, Westphal M. Trk family members: potential lineage markers for glia. I Neurooncol 35, S47 (1997)
   PubMedGoogle Scholar
• Luider Th, van den Bent MJ, Smitt PS, Vecht ChJ, Kros JM. Inventory of proteins in astrocytoma and oligodendroglioma by two-dimensional electrophoresis. Neurooncol 35, S28 (1997).
   Google Scholar
• LeDoux SP, Williams BA, Hollensworth BS et al. Glial cell-specific differences in repair of 06-methylguanine. Cancer Res. 56, 5615–5619 (1996).
   PubMed Web of Science ®Google Scholar
• Mineura K, Yanagisawa T, Watanabe K, Kowada M, Yasui N. Human brain tumor 06-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. kit. J. Cancer 69,420–425 (1996).
   Google Scholar
• Cairncross G, Swinnen L, Bayer R et al Myelo-ablative chemotherapy for recurrent aggressive oligodendroglioma. Neumoncol 2(2), 114–119 (2000).
   Google Scholar
• Peterson K, Paleologos N, Forsyth P et al Salvage chemotherapy for oligodendroglioma. I Neumsurg. 85,597–601 (1996).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Ruda R, Bradac GB et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43, 1066–1073 (1998).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy: Dutch Neuro—oncology Group. Neurology 51,1140–1145 (1998).
   PubMed Web of Science ®Google Scholar
• Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles and Practice of Oncology De Vita VT Jr, Hellman S, Rosenberg SA (Eds), Philadelphia PA, USA, 2022-2082 (1997).
   Google Scholar
• Paleologos NA, Macdonald DR, Vick NA et al Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma. Neurology53,1141–1143 (1999).
   PubMed Web of Science ®Google Scholar
• Hondre S, Chinot 0, Dufour H, Bouillaut P, Braguer D, Grisoli E Temodal (temozolomide) in Nitrosoureas pre-treated malignant glioma patients. Single institute study. I Neurvoncol 39(Suppl.), 151 (1998).
   Google Scholar
• Chinot OL, Honore S, Dufour H et al Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. OncoL 19(9), 2449–2455 (2001).
   Google Scholar
• •Phase 11 clinical trial describes the efficacy and safety of temozolomide in 48 patients with recurrent anaplastic oligodendrogliomas after standard therapy.
   Google Scholar
• Newlands ES, Blackledge GR, Slack JA et al Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br Cancer65, 287–291 (1992).
   Google Scholar
• O'Reilly SM, Newlands ES, Glaser MG et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. Cancer29A, 940–942 (1993).
   Google Scholar
• Newlands ES, O'Reilly SM, Glaser MG et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur j Cancer32A, 2236–2241 (1996).
   Google Scholar
• Reid JM, Stevens DC, Rubin J et al Pharmacokinetics of 3-methyl-(triazen-1-yl) imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res. 3, 2393–2398 (1997).
   Google Scholar
• Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31, 78–82 (1991).
   Web of Science ®Google Scholar
• Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG. Salvage chemotherapy for oligodendroglioma. Neurosurg. 85,597–601 (1996).
   Google Scholar
• Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. I Neurooncol 27, 149–155 (1996).
   Google Scholar
• Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. I Clin. Omni 15, 3427–3432 (1997).
   Google Scholar
• Fine HA, Figg WD, Jaeclde K et al. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. I Clin. Omni 18(4), 708–715 (2000).
   Google Scholar
• Cohen MH. Thalidomide in the treatment of high-grade gliomas. I Clin. Omni 18(19), 3453 (2000).
   Google Scholar
• Fine HA, Maher EA, Wen Y, Batchelor T, Viscosi E, Figg W Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas. Proc. 37th Ann. Soc. Clin. Oncol San Francisco, California, CA, USA, (2001) (Abstract 218).
   Google Scholar
• Lindegaard KF, Mork SJ, Eide GE et al Statistical analysis of clinicopathological features, radiotherapy and survival in 170 cases of oligodendroglioma. I Neurosurg. 67(2), 224–230 (1987).
   Google Scholar
• Karim ABMF, Cornu P, Bleehen N et al Immediate postoperative radiotherapy in low grade glioma improve progression free survival but not overall survival: preliminary results of an EORTC/MRC randomized Phase III study. Proc. 34th Ann. Soc. Clin. Omni (1998) (Abstract 1544).
   Google Scholar
• Henderson KH, Shaw EG. Randomized trials of radiation therapy in adult low-grade gliomas. Sarnia Racliat. Oncol 11 (2), 145–151 (2001).
   Google Scholar
• Karim AB, Maat B, Hatlevoll R et al A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. Racliat. Omni Biol. Phys. 36,549-556 (1996.).
   Google Scholar
• Shaw E, Arusell R, Scheithauer B et al Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Co-operative Oncology Group study. I Clin. Omni 20(9), 2267–2276 (2002).
   Google Scholar